Switching intravenous to subcutaneous infliximab was safe and successful during 1-year follow up in Ulcerative Colitis and Crohn patients – a Belgian single center experience
Switching UC and Crohn patients in clinical remission and adequate trough levels from maintenance IV tot SC infliximab therapy was successful for at least one year. A proportion of patients experienced pain and or injection site reactions.
Authors
- F Baert
- Lobke Desomer (ORCID: https://orcid.org/0000-0002-2783-625X)
- E De Jonckere
- Hilde Vanpoucke
- Leander Cornelis (ORCID: https://orcid.org/0000-0002-6594-9271)
- Julie Bossuyt (ORCID: https://orcid.org/0000-0001-8874-4765)
- Dominiek De Wulf
Institutions
- AZ Delta (BE)
Publication Details
- Journal
- Acta Gastro Enterologica Belgica
- Published
- 2025-03-01
- DOI
- https://doi.org/10.51821/88.1.13222
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82